Literature DB >> 11897584

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.

Enrique J Alvirez-Freites1, Janna L Carter, Michael H Cynamon.   

Abstract

Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis. GAT was subsequently compared in a dose range study to isoniazid (INH) in a murine tuberculosis model. GAT was somewhat less active than INH. GAT and MXF were evaluated in mice infected with M. tuberculosis and were found to have similar activities. GAT was studied alone and in combination with ethambutol, ethionamide (ETA), and pyrazinamide (PZA) and compared to INH and rifampin (RIF). GAT appears to have sufficient activity alone and in combination with ETA with or without PZA to merit evaluation for treatment of tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11897584      PMCID： PMC127120          DOI： 10.1128/AAC.46.4.1022-1025.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  In vitro activity of ofloxacin against Mycobacterium tuberculosis.

Authors:  M C Yu; J Suo; T P Lin; K T Luh
Journal:  J Formos Med Assoc       Date:  1997-01       Impact factor: 3.282

2.  Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.

Authors:  H M Mattoes; M Banevicius; D Li; C Turley; D Xuan; C H Nightingale; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

3.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 4.  The role of fluoroquinolones in tuberculosis today.

Authors:  S E Berning
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis resistance.

Authors:  M Casal; P Ruiz; A Herreras
Journal:  Int J Tuberc Lung Dis       Date:  2000-06       Impact factor: 2.373

6.  Activity of moxifloxacin against mycobacteria.

Authors:  S H Gillespie; O Billington
Journal:  J Antimicrob Chemother       Date:  1999-09       Impact factor: 5.790

7.  In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; A Climent; G Royo
Journal:  Int J Antimicrob Agents       Date:  2001-03       Impact factor: 5.283

8.  Activity of levofloxacin in a murine model of tuberculosis.

Authors:  S P Klemens; C A Sharpe; M C Rogge; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  Inflammatory response following intranasal infection with Mycobacterium avium complex: role of T-cell subsets and gamma interferon.

Authors:  B M Saunders; C Cheers
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare.

Authors:  M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1985-09       Impact factor: 5.191
View more
  28 in total

1.  Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors:  Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

Review 2.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 3.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 4.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

5.  Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Authors:  Muhammad Malik; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 6.  Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.

Authors:  Katherine A Sacksteder; Marina Protopopova; Clifton E Barry; Koen Andries; Carol A Nacy
Journal:  Future Microbiol       Date:  2012-07       Impact factor: 3.165

7.  New anti-tuberculosis agents amongst known drugs.

Authors:  Kathryn E A Lougheed; Debra L Taylor; Simon A Osborne; Justin S Bryans; Roger S Buxton
Journal:  Tuberculosis (Edinb)       Date:  2009-08-20       Impact factor: 3.131

8.  Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.

Authors:  Nicolas Veziris; Chantal Truffot-Pernot; Alexandra Aubry; Vincent Jarlier; Nacer Lounis
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis.

Authors:  Michael H Cynamon; Mary Sklaney
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.

Authors:  Lanfranco Fattorini; Dejiang Tan; Elisabetta Iona; Maurizio Mattei; Federico Giannoni; Lara Brunori; Simona Recchia; Graziella Orefici
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.